201 related articles for article (PubMed ID: 33006444)
1. Characterization and prognostic significance of alternative splicing events in lower-grade diffuse gliomas.
Zhao Z; Li GZ; Liu YQ; Huang RY; Wang KY; Jiang HY; Li RP; Chai RC; Zhang CB; Wu F
J Cell Mol Med; 2020 Nov; 24(22):13171-13180. PubMed ID: 33006444
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
3. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
4. Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes.
Wu F; Liu YW; Li GZ; Zhai Y; Feng YM; Ma WP; Zhao Z; Zhang W
Br J Cancer; 2021 Jul; 125(2):255-264. PubMed ID: 34006924
[TBL] [Abstract][Full Text] [Related]
5. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
7. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
[TBL] [Abstract][Full Text] [Related]
8. Identification of Prognostic Signatures of Alternative Splicing in Glioma.
Zeng Y; Zhang P; Wang X; Wang K; Zhou M; Long H; Lin J; Wu Z; Gao L; Song Y
J Mol Neurosci; 2020 Oct; 70(10):1484-1492. PubMed ID: 32602029
[TBL] [Abstract][Full Text] [Related]
9. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
[TBL] [Abstract][Full Text] [Related]
10. Cell aging related genes can be used to characterize clinical prognoses and further stratify diffuse gliomas.
Yang Y; Chen X; Sun J; Chen S; Yang C; Ma Q; Yang J
Sci Rep; 2021 Sep; 11(1):19493. PubMed ID: 34593910
[TBL] [Abstract][Full Text] [Related]
11. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas.
Sun X; Liu X; Xia M; Shao Y; Zhang XD
J Transl Med; 2019 May; 17(1):159. PubMed ID: 31097021
[TBL] [Abstract][Full Text] [Related]
12. Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data.
Xiong Y; Deng Y; Wang K; Zhou H; Zheng X; Si L; Fu Z
EBioMedicine; 2018 Oct; 36():183-195. PubMed ID: 30243491
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
Qi Y; Chen D; Lu Q; Yao Y; Ji C
Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a 21-mRNA prognostic signature in diffuse lower-grade gliomas.
Song LR; Weng JC; Huo XL; Wang L; Li H; Li D; Wu Z; Zhang JT
J Neurooncol; 2020 Jan; 146(1):207-217. PubMed ID: 31853837
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
17. Classification of diffuse lower-grade glioma based on immunological profiling.
Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W
Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361
[TBL] [Abstract][Full Text] [Related]
18. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
19. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
20. Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification.
Su HX; Yang G; Su F; Hu CX; Zhang T; Ran JT; Guan QL
J Immunol Res; 2022; 2022():2671891. PubMed ID: 35832652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
